Neratinib + capecitabine sustains health-related quality of life in patients with HER2-positive metastatic breast cancer and ≥ 2 prior HER2-directed regimens.
Saved in:
| Title: | Neratinib + capecitabine sustains health-related quality of life in patients with HER2-positive metastatic breast cancer and ≥ 2 prior HER2-directed regimens. |
|---|---|
| Authors: | Moy B; Massachusetts General Hospital Cancer Center, 55 Fruit Street, Boston, MA, 02114, USA. bmoy@mgh.harvard.edu., Oliveira M; Vall D'Hebron University Hospital, Vall D'Hebron Institute of Oncology, Barcelona, Spain., Saura C; Vall D'Hebron University Hospital, Vall D'Hebron Institute of Oncology, Barcelona, Spain., Gradishar W; Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL, USA., Kim SB; Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea., Brufsky A; Magee-Womens Hospital of UPMC, Pittsburgh, PA, USA., Hurvitz SA; University of California Los Angeles/Jonsson Comprehensive Cancer Center, Los Angeles, CA, USA., Ryvo L; Assuta Ashdod Medical Center, Ashdod, Israel., Fagnani D; Azienda Socio-Sanitaria Territoriale Di Vimercate, Vimercate, Italy., Kalmadi S; Ironwood Cancer and Research Center, Chandler, AZ, USA., Silverman P; University Hospitals Cleveland Medical Center, Cleveland, OH, USA., Delaloge S; Gustave Roussy, Villejuif, France., Alarcon J; Servicio de Oncologia, Hospital Universitario Son Espases, Palma de Mallorca, Balearic Islands, Spain., Kwong A; Department of Surgery, Queen Mary Hospital, Hong Kong, Hong Kong., Lee KS; National Cancer Center, Gyeonggi-do, Republic of Korea., Ang PCS; Gleneagles Medical Centre, Singapore, Singapore., Ow SGW; National University Cancer Institute, Singapore, Singapore., Chu SC; Hualien Tzu Chi Medical Center, Hualien, Taiwan., Bryce R; Puma Biotechnology Inc., Los Angeles, CA, USA., Keyvanjah K; Puma Biotechnology Inc., Los Angeles, CA, USA., Bebchuk J; Puma Biotechnology Inc., Los Angeles, CA, USA., Zhang B; Puma Biotechnology Inc., Los Angeles, CA, USA., Oestreicher N; Puma Biotechnology Inc., Los Angeles, CA, USA., Bose R; Washington University School of Medicine, St. Louis, MO, USA., Chan N; Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA. |
| Source: | Breast cancer research and treatment [Breast Cancer Res Treat] 2021 Jul; Vol. 188 (2), pp. 449-458. Date of Electronic Publication: 2021 Apr 28. |
| Publication Type: | Journal Article; Randomized Controlled Trial |
| Journal Info: | Publisher: Kluwer Academic Country of Publication: Netherlands NLM ID: 8111104 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1573-7217 (Electronic) Linking ISSN: 01676806 NLM ISO Abbreviation: Breast Cancer Res Treat Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
